News
Diabetes mellitus and heart failure − interconnected units with complex pathogenesis
Diabetes mellitus (DM) represents a significant risk factor for the development of heart failure. The pathogenesis of this condition is very complex, involving hyperglycemia and other metabolic abnormalities, as well as frequently occurring comorbidities such as hypertension, ischemic heart disease, or diabetic neuropathy. The development of type 2 DM (T2DM) in patients with heart failure (cardiogenic T2DM) is also quite common and is primarily caused by the resistance of peripheral tissues to insulin. The result of cardiogenic DM is further…
Teriflunomide "under the microscope" or what it's like to live with MS in the North
The Teri-LIFE study examined teriflunomide very comprehensively. How does it manage to affect the…
Cardiovascular Interventions with Continued Therapy with Dabigatran − Insights from the GLORIA-AF Study
An analysis using data from an international registry of patients with newly diagnosed atrial…
Smouldering Multiple Sclerosis: How Can MRI Help in Its Identification?
With the changing understanding of the etiopathogenesis of multiple sclerosis, several new…
Teriflunomide vs. Dimethyl Fumarate: Does Their Classification into Different Treatment Lines Have Merit?
Teriflunomide is one of the first-choice medications in the treatment of multiple sclerosis (MS)…
Prevalence of Heart Failure and Its Subtypes in the Population of Developed Countries
In developed countries, heart failure occurs in approximately 2% of the population, with an annual…
Inclisiran − a new addition to the arsenal of dyslipidemia treatment
At the XXIX Congress of the Czech Society of Internal Medicine ČLS JEP, held November 6−9, 2022 in…
Use of Inclisiran in a Patient in Secondary Cardiovascular Prevention
Lowering LDL cholesterol (LDL-c) is one of the primary goals for reducing cardiovascular (CV) risk…
Cenobamate − A Case Study from Slovak Real Practice
Cenobamate is indicated for adjunctive therapy of focal seizures with or without secondary…
Brigatinib in the Therapy of Pretreated Patients with Advanced ALK-Positive NSCLC
A French study analyzed clinical data of pretreated ALK-positive patients with advanced non-small…